Evidence map›Paper›PMID 32541471›Full record

ArticleMedicine2020

Withdrawing mycophenolate mofetil in treating a young kidney transplant recipient with COVID-19: A case report.

Dong Chen, Bo Yang, Yan Zhang, Liang Chen, Lai Wei, Weijie Zhang, Xinqiang Wang, Xiaolin Tong, Zhishui Chen

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 3 pooled it
2.2field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 3 syntheses or guidelines pooled it, 15 citations in OpenAlex.

  1. Effect of immunosuppression maintenance in solid organ transplant recipients with COVID-19: Systematic review and meta-analysis.Transplant infectious disease : an official journal of the Transplantation Society · 2021
    Pooled it
  2. Pooled it
  3. Pooled it
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Dong ChenInstitute of Organ Transplantation, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan.
Bo YangInstitute of Organ Transplantation, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan.ORCID 0000-0002-3183-5567
Yan ZhangGeneral Medical Department, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan.
Liang ChenEndocrinology Department, Guanganmen Hospital, Chinese Academy of Traditional Chinese Medicine, Beijing, China.
Lai WeiInstitute of Organ Transplantation, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan.
Weijie ZhangInstitute of Organ Transplantation, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan.
Xinqiang WangInstitute of Organ Transplantation, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan.
Xiaolin TongEndocrinology Department, Guanganmen Hospital, Chinese Academy of Traditional Chinese Medicine, Beijing, China.
Zhishui ChenInstitute of Organ Transplantation, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan.
Chinese Academy of Medical Sciences & Peking Union Medical College · CNGuang’anmen Hospital · CNEos Neuroscience (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

rationaleCoronavirus disease 2019 (COVID-19) is a novel infectious disease and became a global issue. Treatment of COVID-19 especially in solid organ transplant recipients is empirical and controversial, especially the adjustment of the immunosuppressants. PATIENT CONCERNS: A 29-year-old kidney transplant recipient with the symptoms of COVID-19 pneumonia. DIAGNOSES: COVID-19 pneumonia after kidney transplantation.

interventionsHe was treated with modified immunosuppressants (unchanged dose of tacrolimus and oral corticosteroids while discontinuing mycophenolate mofetil (MMF)), antibiotics, interferon α-2b inhalation and traditional Chinese medicine. OUTCOMES: He recovered from COVID-19 pneumonia after 29 days of hospitalization. And the renal function (measured as blood urea nitrogen, serum creatinine, and urine protein) returned to normal. LESSONS: In certain group of COVID-19 (e.g., mild to moderate cases, young patients without comorbidities), a reduction instead of an overall withdrawal of immunosuppressant in kidney transplant recipients is feasible.

Indexed as

BetacoronavirusKidney TransplantationAdultAnti-Bacterial AgentsAnti-Inflammatory AgentsAntiviral AgentsCoronavirus InfectionsCOVID-19COVID-19 Drug TreatmentDrugs, Chinese HerbalHumansImmunosuppressive AgentsInterferon alpha-2MaleMycophenolic AcidOxygen Inhalation TherapyAnti-Bacterial AgentsAnti-Inflammatory AgentsAntiviral AgentsDrugs, Chinese HerbalImmunosuppressive AgentsInterferon alpha-2Mycophenolic Acid

Identifiers

PMID32541471
PMCPMC7302670
OpenAlexW3034234058

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.